Current Urology Reports

, Volume 14, Issue 5, pp 435–441

β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

DOI: 10.1007/s11934-013-0335-8

Cite this article as:
Andersson, K. Curr Urol Rep (2013) 14: 435. doi:10.1007/s11934-013-0335-8


The new information generated over the last decade on the physiology/pharmacology of the normal bladder and on the pathophysiology of the overactive bladder has resulted in the introduction of a new therapeutic principle, β3-adrenoceptor (AR) agonism, and the approval of mirabegron, a selective agonist at β3-ARs. It may be asked in what respects the β3-AR agonists as a group, and mirabegron in particular, differ from the antimuscarinics, and what can clinically be gained by the β3-AR agonists. In this short review, the mechanisms of action, clinical efficacy, and adverse effect profiles of the two groups of drugs are compared and discussed.


AntimuscarinicsMirabegronMechanisms of actionClinical efficacyAdverse effect profile

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Institute for Regenerative MedicineWake Forest University School of MedicineWinston SalemUSA
  2. 2.Department of Urology, Wake Forest Baptist Medical CenterWinston SalemUSA